Table 1 Shows the criteria for therapeutic response evaluation using RECIST 1.1 and PERCIST 1.0

Complete metabolic response (CMR)

- The target lesion shows absent FDG uptake.

- The target lesion shows decreased SUV less than the liver SUV.

- The disappearance of target lesions.

- Any LN whether target or not must decrease in size to less than 10 mm (short axis).

Partial metabolic response (PMR)

- ≥ 30% decrease or at least 8 SUV decrease between the most intense evaluable lesion on baseline study and the most intense lesion on follow up.

- ≥ 8 SUV decrease in the target lesion.

- No new FDG avid lesions.

- No size increase ≥ 30% regarding the target and nontarget lesions.

- ≥ 30% decrease in the sum of the diameter of the target lesions.

Stable metabolic response (SMR)

- Increase or decrease in the SUV of less than 30%

- No sufficient decrease in the size to be PMR or increase in the size to be PMD

Progressive metabolic disease (PMD)

- The target lesion shows an increase in SUV more than 30% or more than 8 SUVs.

- Development of new lesions.

- Increase in size of target lesion by more than 30%

- ≥ 20% increase in the sum of the diameter of the target lesions (taking the smallest sum as a reference) (at least 5 mm increase).

- Newly developed lesions.